JPRN-C000000080
Completed
未知
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancer - Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancer
Fourth Department of Internal Medicine, Sapporo Medical University0 sites40 target enrollmentStarted: September 1, 2005Last updated:
Conditionsunresectable advanced gastric cancer
Overview
- Phase
- 未知
- Status
- Completed
- Sponsor
- Fourth Department of Internal Medicine, Sapporo Medical University
- Enrollment
- 40
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Exclusion criteria included: active infection; serious complications (severe heart disease, pulmonary fibrosis, interstitial pneumonitis and tendency to bleeding); neuropathy grade 2; edema grade 2 (NCI\-CTC); active concomitant malignancy; symptomatic metastases of the central nervous system; history of drug hypersensitivity (including TXT,CDDP,TS\-1 or G\-CSF); serious diarrhea; pregnant and lactating females; females of childbearing age, unless using effective contraception; and other serious medical conditions.
Investigators
Similar Trials
Completed
Phase 2
Phase II study of the combination of docetaxel, cisplatin plus S-1(DCS) for advanced or recurrent gastric cancer(KDOG 0601)Gastric cancerJPRN-UMIN000001119Department of Gastroenterology, Kitasato University School of Medicine45
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)EUCTR2005-005464-92-DESanofi-aventis groupe270
Active, not recruiting
Phase 1
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimen)EUCTR2005-005464-92-GBSanofi-aventis groupe270